L. Bengrine Lefevre
Centre Georges François Leclerc(FR)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, Endometrial and Cervical Cancer Treatments, Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Prognostic Impact of Positive Surgical Margins After Resection of Colorectal Cancer Liver Metastases: Reappraisal in the Era of Modern Chemotherapy(2013)62 cited
- → Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial(2024)24 cited
- → Taking care of older patients with cancer in the context of COVID-19 pandemic(2020)19 cited
- → LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial(2023)19 cited
- → Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial(2022)17 cited
- → Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)(2020)17 cited
- → Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study(2022)12 cited
- → Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis(2022)10 cited
- → Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study(2023)7 cited
- → Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial(2025)4 cited